Marjan A Versnel

List of Publications by Year
in descending order

52	2,232	279701 23	233338 45
papers	citations	h-index	g-index

52	52	52	2947
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum interferon-Î±2 measured by single-molecule array associates with systemic disease manifestations in SjÃ¶grenâ€™s syndrome. Rheumatology, 2022, 61, 2156-2166.	0.9	8
2	Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2022, 61, 3491-3496.	0.9	11
3	Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study. Rheumatology, 2022, 61, 4344-4354.	0.9	9
4	Blood myxovirus resistance proteinâ€1 measurement in the diagnostic workâ€up of suspected COVIDâ€19 infection in the emergency department. Immunity, Inflammation and Disease, 2022, 10, e609.	1.3	4
5	Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2022, 13, 836824.	2.2	5
6	Innate immunity and interferons in the pathogenesis of SjÃ¶grenâ€™s syndrome. Rheumatology, 2021, 60, 2561-2573.	0.9	41
7	Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in SjÃ¶grenâ€™s Syndrome. Journal of Clinical Medicine, 2021, 10, 532.	1.0	7
8	Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110226.	2.5	12
9	Revisiting the JOQUER trial: stratification of primary SjÃ¶grenâ€™s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatology International, 2021, 41, 1593-1600.	1.5	13
10	LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Science and Medicine, 2021, 8, e000571.	1.1	16
11	Hydroxychloroquine treatment downregulates systemic interferon activation in primary SjÃ¶grenâ€™s syndrome in the JOQUER randomized trial. Rheumatology, 2020, 59, 107-111.	0.9	50
12	Inverse correlation between serum complement component C1q levels and whole blood typeâ€I interferon signature in active tuberculosis and QuantiFERONâ€positive uveitis: implications for diagnosis. Clinical and Translational Immunology, 2020, 9, e1196.	1.7	5
13	Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardiâ€GoutiÃ¨res Syndrome, a Type I Interferonopathy. Arthritis and Rheumatology, 2019, 71, 829-831.	2.9	41
14	Associations of cigarette smoking with disease phenotype and type I interferon expression in primary SjÃ¶grenâ€™s syndrome. Rheumatology International, 2019, 39, 1575-1584.	1.5	7
15	MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology, 2019, 58, 1302-1303.	0.9	11
16	Fatigue in SjÃ¶gren's Syndrome: A Search for Biomarkers and Treatment Targets. Frontiers in Immunology, 2019, 10, 312.	2.2	18
17	THU0240â€…GENE EXPRESSION SIGNATURES ARE RELATED TO SPECIFIC SUBSETS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
18	Systemic interferon type I and type II signatures in primary SjÃ¶grenâ€™s syndrome reveal differences in biological disease activity. Rheumatology, 2018, 57, 921-930.	0.9	102

#	Article	IF	Citations
19	TBK1: A key regulator and potential treatment target for interferon positive SjÃ¶gren's syndrome, systemic lupus erythematosus and systemic sclerosis. Journal of Autoimmunity, 2018, 91, 97-102.	3.0	58
20	Type 1 interferon-inducible gene expression in QuantiFERON Gold TB-positive uveitis: A tool to stratify a high versus low risk of active tuberculosis?. PLoS ONE, 2018, 13, e0206073.	1.1	6
21	Interferon activation in primary SjÃ¶grenâ€™s syndrome: recent insights and future perspective as novel treatment target. Expert Review of Clinical Immunology, 2018, 14, 817-829.	1.3	25
22	Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?. Arthritis Research and Therapy, 2018, 20, 4.	1.6	41
23	Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 721-730.	0.5	77
24	The Immune Pathogenesis of Type 1 Diabetes: Not Only Thinking Outside the Cell but Also Outside the Islet and Out of the Box. Diabetes, 2016, 65, 2130-2133.	0.3	16
25	Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Annals of the Rheumatic Diseases, 2016, 75, e81-e81.	0.5	50
26	Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3â€Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferonâ€Positive Primary SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1688-1699.	2.9	45
27	Bone Mineral Density in SjÃ¶gren Syndrome Patients with and Without Distal Renal Tubular Acidosis. Calcified Tissue International, 2016, 98, 573-579.	1.5	9
28	The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Annals of the Rheumatic Diseases, 2016, 75, 1567-1573.	0.5	126
29	The clinical relevance of animal models in SjÃ¶grenâ€™s syndrome: the interferon signature from mouse to man. Arthritis Research and Therapy, 2015, 17, 172.	1.6	26
30	Prevalence of distal renal tubular acidosis in primary SjÃ¶gren's syndrome. Rheumatology, 2015, 54, 933-939.	0.9	40
31	The Gene Expression Profile of CD11c+CD8Î±â¯ Dendritic Cells in the Pre-Diabetic Pancreas of the NOD Mouse. PLoS ONE, 2014, 9, e103404.	1.1	7
32	T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?. Arthritis Research and Therapy, 2014, 16, R62.	1.6	37
33	Type I IFN signature in primary SjÃ¶grenâ€™s syndrome patients. Expert Review of Clinical Immunology, 2014, 10, 457-467.	1.3	33
34	MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2014, 73, 1052-1059.	0.5	98
35	Prevalence of interferon type I signature in CD14 monocytes of patients with SjÃ¶gren's syndrome and association with disease activity and BAFF gene expression. Annals of the Rheumatic Diseases, 2013, 72, 728-735.	0.5	263
36	The Kinetics of Plasmacytoid Dendritic Cell Accumulation in the Pancreas of the NOD Mouse during the Early Phases of Insulitis. PLoS ONE, 2013, 8, e55071.	1.1	18

#	Article	IF	Citations
37	Reduced numbers of dendritic cells with a tolerogenic phenotype in the prediabetic pancreas of NOD mice. Journal of Leukocyte Biology, 2012, 92, 1207-1213.	1.5	19
38	The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics, 2010, 10, 59-76.	1.4	245
39	Systemic increase in typeâ€„I interferon activity in SjÃ¶gren's syndrome: A putative role for plasmacytoid dendritic cells. European Journal of Immunology, 2008, 38, 2024-2033.	1.6	163
40	NOD mice have a severly impaired ability to recruit leukocytes into sites of inflammation. European Journal of Immunology, 2005, 35, 225-235.	1.6	39
41	Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. European Journal of Immunology, 2005, 35, 2386-2396.	1.6	39
42	Increased Serum Levels of MRP-8/14 in Type 1 Diabetes Induce an Increased Expression of CD11b and an Enhanced Adhesion of Circulating Monocytes to Fibronectin. Diabetes, 2004, 53, 1979-1986.	0.3	102
43	Id3 Knockout Mice as a New Model for SjÃ¶gren's Syndrome. Immunity, 2004, 21, 457-458.	6.6	9
44	Proapoptosis and Antiapoptosis-Related Molecules During Postnatal Pancreas Development in Control and Nonobese Diabetic Mice: Relationship with Innervation. Laboratory Investigation, 2003, 83, 227-239.	1.7	17
45	Localization and Potential Role of Matrix Metalloproteinase-1 and Tissue Inhibitors of Metalloproteinase-1 and -2 in Different Phases of Bronchopulmonary Dysplasia. Pediatric Research, 2001, 50, 761-766.	1.1	24
46	Two Different Types of Sialoadenitis in the NOD- and MRL/lpr Mouse Models for SjÃ¶grenâ€™s Syndrome: A Differential Role for Dendritic Cells in the Initiation of Sialoadenitis?. Laboratory Investigation, 2000, 80, 575-585.	1.7	52
47	Professional Antigen Presenting Cells in Minor Salivary Glands in SjÃ¶grenâ€™s Syndrome: Potential Contribution to the Histopathological Diagnosis?. Laboratory Investigation, 2000, 80, 1935-1941.	1.7	29
48	The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. , 1998, 75, 649-653.		84
49	Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. International Journal of Cancer, 1996, 67, 393-398.	2.3	10
50	Expression of the wilms' tumor geneWT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes and Cancer, 1995, 12, 87-96.	1.5	47
51	Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression. FEBS Journal, 1992, 208, 589-596.	0.2	15
52	Trained Immunity in Primary SjÃ¶grenâ€™s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype. Frontiers in Immunology, 0, 13, .	2.2	3